Alisertib Induces Early Signals of Efficacy in Endocrine-Resistant Breast Cancer

Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.

Related Keywords

Minnesota ,United States ,Tufiac Haddad ,Antonio Dassoro , ,Practice Innovation ,Mayo Clinic Comprehensive Cancer Center ,Antoniod Assoro ,Puma Biotechnology ,Alisertib ,Aurka Pathway ,Endocrine Resistant Advanced Breast Cancer ,Fulvestrant ,A Phase 2 Trial Nct02860000 ,Her2 Negative Metastatic Breast Cancer ,